Introduction {#S1}
============

The rapid emergence and spread of multidrug resistant organisms (MDROs) in hospitals is a growing problem worldwide \[[@R01], [@R02]\]. Hospital-acquired infections, particularly those caused by MDROs, are associated with excess mortality and morbidity as well as increased hospital costs \[[@R03]-[@R07]\]. Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), and multidrug resistant (MDR) gram-negative pathogens commonly cause hospital-acquired infections \[[@R08]\]. Managing hospital-acquired infections and MDROs is a daily challenge in hospitals, especially from the perspective of critical care.

Universal decolonization using topical antiseptic agents that reduce the population of microorganisms on patients\' skin represents a simple, cost-effective way to prevent healthcare-associated infections \[[@R09], [@R10]\]. Universal decolonization by daily bathing of ICU patients with chlorhexidine digluconate (CHG)-impregnated cloths resulted in a substantial reduction in bloodstream infections and MRSA acquisition \[[@R09], [@R11]-[@R13]\]. CHG-impregnated cloths have also proven effective in reducing the skin burden of MRSA and VRE in ICU patients \[[@R09], [@R14], [@R15]\].

Evidence suggests that skin colonization with gramnegative bacterial pathogens may be a root cause of hospital- acquired infections. ICU patients who have diarrhea can be particularly at risk of gram-negative bacteria dissemination from feces to skin areas on distant parts of the body \[[@R16]\]. There is less information concerning the utility of CHG on antibiotic-resistant gram-negative bacteria \[[@R15]\], although a recent study showed that a proprietary CHG formulation reduced hospital-acquired infections caused by gram-negative bacteria \[[@R17]\]. The objective of this study was to quantify *in vitro* the antimicrobial effectiveness of a proprietary CHG formulation used in one brand of CHG-impregnated cloths against gram-negative MDR and extensively drug resistant (XDR) clinical isolates (e.g., *Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii*), as well as against clinical isolates of MRSA and VRE.

Materials and methods {#S2}
=====================

BACTERIAL ISOLATES {#S2a}
------------------

Clinical isolates of *P. aeruginosa*, *K. pneumoniae*, *E. coli*, and *A. baumannii* selected for testing were classified as MDR or XDR as described elsewhere \[[@R18]\]. Clinical isolates of MRSA and vancomycin-resistant *E. faecium* were also tested. Ten consecutive isolates per species were collected from patients who were diagnosed with an infection cause by a MDRO during their stay in at the Heidelberg University Hospital, Germany, in 2014.

FORMULATIONS AND NEUTRALIZER {#S2b}
----------------------------

A proprietary 2% CHG formulation (Sage Products LLC, Cary, Illinois, US) was tested. The solution used to neutralize the antimicrobial properties of the CHG was composed of Caso-bouillon and LTHTh (Heipha, Eppelheim, Germany).

TIME KILL ASSAYS {#S2c}
----------------

The antimicrobial properties of the proprietary CHG formulation at concentrations of 2% (20 mg/ml, the original proprietary formulation concentration), 1% (10 mg/mL), and 0.5% (5 mg/mL) were determined using the quantitative suspension methods described by Gebel et al. \[[@R19]\]. Briefly, bactericidal efficacy was determined without organic load. The CHG formulation was diluted in water of standardized hardness. One milliliter of the test organism suspension and 1 mL of sterile water of standardized hardness were mixed and incubated for 2 minutes, after which the test substance was added. The resulting solutions were incubated for 1, 3, and 9 minutes, respectively; gram-negative organisms were also incubated for 15 seconds, based on the test procedures outlined in the *FDA Tentative Final Monograph for Topical Antimicrobial Drug Products for Over-The-Counter Human Use* (59 FR, 31444, June 17, 1994). At the end of the incubation time, 1 mL of the test solution was transferred to 10 mL of Caso-bouillon and LTHTh and neutralized for 5 minutes. Thereafter, 100 μl and 500 μl of the neutralized test solution was spread onto two agar plates. After incubation for 24 hours at 37 °C the colony forming units (CFU) were counted. The log 10 reduction was determined as the logarithm to the base 10 of the difference between the number of cells in the test solution at the beginning of the contact time and at the end.

DETERMINATION OF THE MINIMUM INHIBITORY CONCENTRATION (MIC) {#S2d}
-----------------------------------------------------------

MIC testing procedures were adapted based on those outlined in the *FDA Tentative Final Monograph for Topical Antimicrobial Drug Products for Over-The-Counter Human Use* (59 FR, 31444, June 17, 1994). Briefly, a 96-well microtiter plate (Sarstedt, Nümbrecht, Germany) containing doubling dilutions of the proprietary CHG in RPMI medium (Gibco, Darmstadt, Germany) was set up. CHG concentrations started at 2% and were then diluted by half. Concentrations for MIC testing were diluted down to 1 : 65,536. Wells containing only RPMI were used as growth controls. An overnight broth culture of each isolate was standardized to 1 x 108 CFU/mL and 50 μL volumes of this were added to the microtiter plate. Serial dilutions were done and CFUs counted on the plates to achieve a concentration of 1 x 10^5^. Plates were incubated for 24 hours at 37 °C. The MIC was defined as the lowest concentration of CHG at which no bacterial growth was observed visually on the microtiter plate. Conversion of resazurin to resarafin (Sigma-Aldrich, Hamburg, Germany) was used as a visual indicator.

Results {#S3}
=======

ISOLATES {#S3a}
--------

Ten isolates each of VRE, MRSA, XDR *P. aeruginosa*, XDR *K. pneumoniae*, and *E. coli* were collected and tested. Nine isolates of MDR *A. baumannii* and one of XDR *A. baumannii* were collected and tested.

IN VITRO TIME KILL STUDIES {#S3b}
--------------------------

All isolates were highly susceptible to the proprietary CHG formulation ([Fig. 1](#F1){ref-type="fig"}). Suppression rates were 99% to 100% for all isolates, at all concentrations including the lower concentrations of 1% (10 mg/mL) and 0.5% (5 mg/mL). The 0.5% CHG formulation provided a 99.9% reduction of XDR *P. aeruginosa*, XDR *K. pneumoniae*, XDR *E. coli*, and XDR and MDR *A. baumannii* from the earliest 15-second time point, and for MRSA and VRE at the earliest 1 minute time point.

![Time kill at 1 minute with a 2% CHG proprietary solution of clinical isolates of MRSA, vancomycin-resistant *E. faecium*, and the *XDR gram-negative pathogens P. aeruginosa*, *K. pneumoniae*, *E. coli*, and *A. baumannii*.](2421-4248-56-E176-g001){#F1}

MIC DETERMINATIONS {#S3c}
------------------

MICs for the proprietary CHG solution against MRSA ranged from 1 : 4096 for a single isolate to 1 : 65536 ([Tab. I](#T1){ref-type="table"}). Nine out of ten XDR *E. coli* isolates had an MIC of 1 : 4096 with the CHG formulations. XDR *A. baumannii* showed relatively low MICs, with an MIC of 1 : 1024. Vancomycin-resistant *E. faecium* most commonly demonstrated MICs of 1 : 2048. XDR *K. pneumonia* and XDR *P. aeruginosa* had slightly higher MICs. The MICs for *P. aeruginosa* MICs ranged from 1 : 512 to 1 : 1024. MICs for XDR *K. pneumoniae* ranged from 1 : 512 to 1 : 4096.

###### 

MICs of a proprietary CHG formulation against ten clinical isolates of MRSA, vancomycin-resistant *E. faecium*, and the XDR gramnegative pathogens *P. aeruginosa*, *K. pneumoniae*, *E. coli*, and *A. baumannii* demonstrate the susceptibility of MDR isolates.

  Clinical isolates           Number of isolates   MIC
  --------------------------- -------------------- ----------
  ***S. aureus (MRSA)***      1                    1 : 4096
  3                           1 : 8192             
  5                           1 : 16384            
  1                           1 : 65536            
  ***E. faecium (VRE)***      2                    1 : 1024
  8                           1 : 2048             
  ***P. aeruginosa (XDR)***   7                    1 : 512
  3                           1 : 1024             
  ***K. pneumoniae (XDR)***   7                    1 : 512
  2                           1 : 1024             
  1                           1 : 4096             
  ***E.coli (XDR)***          1                    1 : 2048
  9                           1 : 4096             
  ***A. baumannii (XDR)***    1                    1 : 512
  6                           1 : 1024             
  2                           1 : 2048             
  ***A. baumannii (MDR)***    1                    1 : 1024

Discussion {#S4}
==========

Hospital-acquired infections are leading causes of preventable morbidity and mortality \[[@R02], [@R20]\]. Skin decolonization with CHG-impregnated cloths has been shown to reduce the risk of some types of these infections \[[@R11], [@R09], [@R12], [@R13], [@R16], [@R21]\]. This method was shown to be an effective and cost saving way to reduce the risk of transmission of MDROs such as MRSA and VRE in the hospital, a setting where rapid emergence and spread of MDROs is well known \[[@R09], [@R12], [@R15], [@R10], [@R01]\]. The *in vitro* time kill studies confirmed that all of the German clinical isolates tested, including MDR and XDR gram-negative bacteria, MRSA, and vancomycin-resistant *E. faecium*, were highly susceptible to all concentrations of the proprietary CHG formulation used. This was true at the earliest time point tested (15 seconds). These results corroborate and quantify the effectiveness of the proprietary CHG formulation against clinical isolates of MDR and XDR gram-negative bacteria *in vitro*.

MIC data were more variable than time kill data. We observed relatively low MICs for MRSA, *E. coli*, *A. baumannii* and vancomycin-resistant *E. faecium*, but higher MICs for *P. aeruginosa* and *K. pneumoniae*. Lack of a consistent relationship between the CHG MIC and increased CHG killing has been described previously with MRSA \[[@R22]\]. The authors noted that the MIC did not appear to affect *in vitro* rate of kill or *in vivo* skin test results, and did not represent CHG resistance. The discordance between MIC and kill rate did not affect the utility of CHG decolonization in that study, and the same may well be true for the pathogens we studied. For example, even the MICs we observed against *P. aeruginosa* (e.g., 19.53 μg/mL or 1 : 512) would be at least 10-fold lower than the lowest concentrations of CHG deposited on skin when the 2% proprietary CHG formulation was used \[[@R11]\]. We conducted our *in vitro* evaluations using the proprietary CHG formulation specifically because the CHG impregnated cloths have been shown to provide consistently high concentrations of antiseptic coverage when applied to skin \[[@R11]\].

Conclusions {#S5}
===========

The present study provides *in vitro* evidence that the proprietary CHG formulation is effective against MDR gram-negative organisms, MRSA, and VRE. The solution we studied is available only in CHG-impregnated cloths which are known to provide effective protection against colonization and infection by drug resistant pathogens. Of course, the 60 clinical isolates tested would not be representative of all strains a patient might encounter in a German hospital. In addition, higher concentrations of the CHG product than were tested *in vitro* may also be more representative of the amount deposited by cloths in real-life use. Future research should evaluate the potential of the cloths to prevent MDROs from colonizing the skin and leading to hospital-acquired infections.
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